Hsbc Holdings PLC Lowers Stake in Insulet Corporation $PODD

Hsbc Holdings PLC decreased its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 5.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 165,958 shares of the medical instruments supplier's stock after selling 10,009 shares during the quarter. Hsbc Holdings PLC owned 0.24% of Insulet worth $25,341,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its holdings in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock valued at $54,000 after buying an additional 64 shares during the period. Cresset Asset Management LLC boosted its holdings in Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier's stock valued at $813,000 after acquiring an additional 177 shares during the period. Cerity Partners LLC boosted its holdings in Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier's stock valued at $5,423,000 after acquiring an additional 7,030 shares during the period. Sei Investments Co. boosted its holdings in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier's stock valued at $43,245,000 after acquiring an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier's stock valued at $10,290,000 after acquiring an additional 791 shares in the last quarter.

Insulet Stock Down 3.5%

PODD stock opened at $142.28 on Wednesday. The company's 50 day moving average price is $154.04 and its 200 day moving average price is $175.76. The firm has a market capitalization of $9.87 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 1.16 and a beta of 1.08. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm's revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on PODD shares. Weiss Ratings lowered shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, June 24th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Evercore set a $180.00 target price on shares of Insulet in a report on Monday, July 6th. Royal Bank Of Canada decreased their price target on shares of Insulet from $245.00 to $160.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, William Blair assumed coverage on shares of Insulet in a research note on Wednesday, May 20th. They issued an "outperform" rating for the company. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Insulet has an average rating of "Hold" and an average target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.